From: Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
Parameter | baseline | day 2 | day 14 | (female) | ||
---|---|---|---|---|---|---|
vehicle | Nz-800CW | vehicle | Nz-800CW | |||
mean ± sd | mean ± sd | mean ± sd | unit | |||
A:G Ratio | 2.0 ± 0.1 | 1.9 ± 0.4 | 2.1 ± 0.3 | 2.4 ± 0.2 | 2.3 ± 0.2 | |
ALT | 27.2 ± 4.8 | 41.5 ± 21.1 | 26.2 ± 2.9 | 23.8 ± 7.2 | 30.5 ± 11.2 | U/L |
Albumin | 32.0 ± 2.2 | 31.8 ± 3.4 | 32.2 ± 1.5 | 32.0 ± 0.7 | 33.5 ± 0.6 | g/L |
Alk Phos | 123 ± 15 | 150 ± 20 | 164 ± 12 | 128 ± 8 | 134 ± 10 | U/L |
Amylase | 2332 ± 292 | 2537 ± 139 | 2819 ± 480 | 2335 ± 140 | 2307 ± 123 | U/L |
CK | 413 ± 182 | 1248 ± 391 | 696 ± 254 | 805 ± 661 | 352 ± 193 | U/L |
Calcium | 2.4 ± 0.2 | 2.4 ± 0.1 | 2.1 ± 0.3 | 2.5 ± 0.1 | 2.3 ± 0.1 | mmol/L |
Chloride | 105 ± 0.6 | 101 ± 6 | 108 ± 5 | 106 ± 2 | 106 ± 1 | mmol/L |
Cholesterol | 2.5 ± 0.2 | 2.3 ± 0.3 | 2.2 ± 0.1 | 2.3 ± 0.2 | 2.4 ± 0.2 | mmol/L |
Creatinine | 17.8 ± 3.0 | 15.8 ± 1.7 | 13.5 ± 1.7 | 15.0 ± 3.3 | 16.2 ± 1.3 | μmol/L |
GLDH | 10.0 ± 2.9 | 13.5 ± 4.0 | 13.0 ± 1.7 | 9.0 ± 2.8 | 8.2 ± 3.0 | U/L |
Globulin | 15.8 ± 0.5 | 16.5 ± 1.7 | 15.5 ± 1.7 | 13.6 ± 1.3 | 14.5 ± 1.3 | g/L |
Glucose | 15.2 ± 1.6 | 13.4 ± 1.6 | 12.9 ± 1.5 | 15.0 ± 1.1 | 14.8 ± 0.6 | mmol/L |
Lipase | 25.8 ± 3.6 | 26.8 ± 2.9 | 26.0 ± 2.2 | 27.0 ± 2.5 | 26.8 ± 2.2 | U/L |
Magnesium | 1.2 ± 0.1 | 1.1 ± 0.1 | 1.0 ± 0.1 | 1.1 ± 0.1 | 1.2 ± 0.1 | mmol/L |
Na:K Ratio | 39.8 ± 1.3 | 33.5 ± 5.8 | 41.0 ± 7.1 | 42.4 ± 4.6 | 42.3 ± 3.8 | |
Phosphorus | 3.3 ± 0.3 | 2.7 ± 0.4 | 2.3 ± 0.3 | 2.8 ± 0.4 | 2.8 ± 0.3 | mmol/L |
Potassium | 3.7 ± 0.1 | 4.3 ± 0.7 | 3.7 ± 0.6 | 3.6 ± 0.3 | 3.6 ± 0.4 | mmol/L |
Sodium | 149 ± 0.5 | 144 ± 5 | 149 ± 4 | 150 ± 2 | 152 ± 1.5 | mmol/L |
Total Bilirubin | 0.4 ± 0.2 | 0.0 ± 0.0 | 0.3 ± 0.5 | 0.2 ± 0.3 | 0.6 ± 0.8 | μmol/L |
Total Protein | 47.8 ± 2.2 | 48.2 ± 1.7 | 47.8 ± 1.3 | 45.6 ± 1.9 | 48.0 ± 1.4 | g/L |
Urea | 9.7 ± 0.9 | 10.9 ± 1.4 | 10.8 ± 1.0 | 10.2 ± 0.7 | 9.0 ± 1.0 | mmol/L |